Rep. Josh Gottheimer bought Gilead Sciences (GILD)
Rep. Josh Gottheimer (D-NJ-5) · $1K–$15K · traded Mar 7, 2025
- Transaction
- Bought
- Amount
- $1K–$15K
- Owner
- Joint
- Traded
- Mar 7, 2025
- Disclosed
- Apr 10, 2025
- Days to disclose
- 34
- Asset type
- Stock
- As filed
- Gilead Sciences, Inc. - Common Stock
- Industry
- Drug Manufacturers - General · Healthcare
Other trades in this filing
All of Gottheimer's trades →- Apr 10, 2025$1K–$15K
$1K–$15K · Traded Mar 24, 2025 · disclosed Apr 10, 2025 · Joint
Committee overlap: Financial ServicesGot $13K from the company’s PAC - Apr 10, 2025$1K–$15K
Sold (partial) Spotify Technology SPOT
$1K–$15K · Traded Mar 24, 2025 · disclosed Apr 10, 2025 · Joint
- Apr 10, 2025$1K–$15K
$1K–$15K · Traded Mar 19, 2025 · disclosed Apr 10, 2025 · Joint
- Apr 10, 2025$1K–$15K
Sold Crinetics Pharmaceuticals CRNX
$1K–$15K · Traded Mar 19, 2025 · disclosed Apr 10, 2025 · Joint
- Apr 10, 2025$1K–$15K
$1K–$15K · Traded Mar 19, 2025 · disclosed Apr 10, 2025 · Joint
- Apr 10, 2025$1K–$15K
Sold Perusahaan Perseroan (Persero) PT Telekomunikasi Indonesia Tbk TLK
$1K–$15K · Traded Mar 19, 2025 · disclosed Apr 10, 2025 · Joint
- Apr 10, 2025$1K–$15K
Sold Techtronic Industries Company Limited TTNDY
$1K–$15K · Traded Mar 19, 2025 · disclosed Apr 10, 2025 · Joint
- Apr 10, 2025$1K–$15K
$1K–$15K · Traded Mar 19, 2025 · disclosed Apr 10, 2025 · Joint
- Apr 10, 2025$1K–$15K
$1K–$15K · Traded Mar 19, 2025 · disclosed Apr 10, 2025 · Joint
- Apr 10, 2025$1K–$15K
$1K–$15K · Traded Mar 19, 2025 · disclosed Apr 10, 2025 · Joint
Got $8K from the company’s PAC - Apr 10, 2025$1K–$15K
$1K–$15K · Traded Mar 19, 2025 · disclosed Apr 10, 2025 · Joint
- Apr 10, 2025$1K–$15K
Sold (partial) Chord Energy CHRD
$1K–$15K · Traded Mar 19, 2025 · disclosed Apr 10, 2025 · Joint
- Apr 10, 2025$1K–$15K
$1K–$15K · Traded Mar 19, 2025 · disclosed Apr 10, 2025 · Joint
- Apr 10, 2025$1K–$15K
$1K–$15K · Traded Mar 19, 2025 · disclosed Apr 10, 2025 · Joint
- Apr 10, 2025$1K–$15K
$1K–$15K · Traded Mar 19, 2025 · disclosed Apr 10, 2025 · Joint
- Apr 10, 2025$1K–$15K
$1K–$15K · Traded Mar 19, 2025 · disclosed Apr 10, 2025 · Joint
- Apr 10, 2025$1K–$15K
$1K–$15K · Traded Mar 19, 2025 · disclosed Apr 10, 2025 · Joint
- Apr 10, 2025$1K–$15K
$1K–$15K · Traded Mar 19, 2025 · disclosed Apr 10, 2025 · Joint
- Apr 10, 2025$1K–$15K
Sold Tandem Diabetes Care TNDM
$1K–$15K · Traded Mar 19, 2025 · disclosed Apr 10, 2025 · Joint
- Apr 10, 2025$1K–$15K
$1K–$15K · Traded Mar 19, 2025 · disclosed Apr 10, 2025 · Joint
Recent Congress trades in GILD
- Jul 21, 2026$1K–$15K
Sen. Alan Armstrong (R-OK)
$1K–$15K · Traded Mar 27, 2026 · disclosed Jul 21, 2026 · filed 116 days later
Committee overlap: HELP - Jun 19, 2026$1K–$15K
Rep. Jared Moskowitz (D-FL-23)
$1K–$15K · Traded May 6, 2026 · disclosed Jun 19, 2026
- Jun 19, 2026$1K–$15K
Rep. Jared Moskowitz (D-FL-23)
$1K–$15K · Traded May 6, 2026 · disclosed Jun 19, 2026 · Dependent
- Feb 26, 2026$1K–$15K
Rep. Josh Gottheimer (D-NJ-5)
$1K–$15K · Traded Jan 27, 2026 · disclosed Feb 26, 2026 · Joint
- Oct 10, 2025$1K–$15K
Rep. Val T. Hoyle (D-OR-4)
$1K–$15K · Traded Sep 23, 2025 · disclosed Oct 10, 2025 · Spouse
- Sep 12, 2025$1K–$15K
Rep. Val T. Hoyle (D-OR-4)
$1K–$15K · Traded Oct 29, 2024 · disclosed Sep 12, 2025 · Spouse · filed 318 days later
- Jun 22, 2025$15K–$50K
Rep. Jefferson Shreve (R-IN-6)
$15K–$50K · Traded May 12, 2025 · disclosed Jun 22, 2025
- Jun 18, 2025$1K–$15K
Rep. Marjorie Taylor Greene (R-GA-14)
$1K–$15K · Traded Jun 6, 2025 · disclosed Jun 18, 2025
Company context for GILD
Recent records for the company. These may have been published before or after this trade; compare the dates before drawing a connection.
GILD: 10-Q financial filing
Filed 10-Q for an event or period dated 2026-09-30. Read the company report for its disclosures.
GILD: Financial results
Filed 8-K for an event or period dated 2026-10-29. Financial results.
GILD: third_quarter 2026 lobbying report
Advocate on domestic and global drug pricing proposals, international trade and protection of intellectual property; global supply chain issues, including the Medical Supply Chain Resiliency Act and tariffs; compulsory licensing and other IP issues in multiple countries. Funding for policies relating to domestic and international HIV, Hepatitis C, oncology, and public health activities via appropriations. Advocacy regarding drug pricing proposals, including provisions modifying the Inflation Reduction Act and government purchasing proposals. Advocate on drug pricing proposals. Proposals to exp
Public: Oct 21, 2026, 1:36 PM EDTOriginal source ↗
From a periodic transaction report filed under the STOCK Act. Amounts are the ranges members report. Nothing here is investment advice.